Companies announce new GDNF development collaboration for diseases of CNS

MedGenesis Therapeutix Inc., a biopharmaceutical company working on CNS diseases, announced an agreement with Amgen Inc. The agreement grants MedGenesis a worldwide license for glial cell line-derived neurotrophic factor protein (GDNF) for both CNS and non-CNS indications. While the initial focus of drug development will be for Parkinson’s Disease, GDNF has also been shown to have robust survival-promoting activity for motorneurons, the cells damaged in ALS.

Click here to read more.

Share this: